Home > Insider Trading > Filing (0001225208-13-004681)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
14272	Bristol Myers Squibb Co	BMY	Pharmaceutical Preparations (2834)	220790350

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1341069	C Joseph Caldarella	Bristol-Myers Squibb Company 345 Park Avenue New York NY 10154	Svp & Controller	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.10 Par Value	Acquisiton	2013-02-20	22,598	$27.01	76,257	No	4	M	Direct
Common Stock, $0.10 Par Value	Acquisiton	2013-02-20	17,710	$22.73	93,967	No	4	M	Direct
Common Stock, $0.10 Par Value	Disposition	2013-02-20	37,585	$36.87	56,382	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, $0.10 Par Value	Option (right to buy)	Disposition	2013-02-20	22,598	$0.00	22,598	$27.01
Common Stock, $0.10 Par Value	Option (right to buy)	Disposition	2013-02-20	17,710	$0.00	17,710	$22.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2017-03-05	No	4	M	Direct
0		2016-03-06	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.10 Par Value	1,583	Indirect	By BMY Savings & Investment Program

Footnotes

The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.87 to $36.89, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Based on a plan statement as of the end of the most recent fiscal quarter.
Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007.
Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 7, 2006.